Navigation Links
Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
Date:9/24/2010

SAN DIEGO, Sept. 24 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd. Proceeds from the financing will be used to expand the human clinical trials program for CX-4945, including the Phase I trial in patients with multiple myeloma and a series of randomized Phase II trials.

The multi-center Phase I study with CX-4945 will be conducted in patients with relapsed or refractory multiple myeloma. The primary objectives of the study are to determine the safety, tolerance and pharmacokinetic (PK) properties of CX-4945 in multiple myeloma patients and to select the appropriate dose for Phase II trials. Secondary objectives are to investigate the pharmacodynamic (PD) activity of CX-4945 using mechanism and tumor-related PD biomarkers that have been validated in both preclinical and clinical studies. In preclinical studies with multiple myeloma cell lines, CX-4945 inhibited critical CK2-mediated events including key signaling pathways and mediators (PI3K/Akt, NFkB, IL-6) that are known to drive the proliferation of multiple myeloma. These findings, coupled with the need for new agents that target molecular pathways shared by all subtypes of multiple myeloma, highlight CX-4945 as a promising therapeutic agent for multiple myeloma.

A separate Phase I clinical trial in patients with solid tumors evaluating CX-4945 as an orally administered single agent has already established favorable pharmacokinetic and safety profiles. Measurement of mechanism and tumor-related biomarkers in patients established that CX-4945 hits the CK2 target and down-modulates the PI3K/Akt pathway. Together, the PK and PD data demonstrate that CX-4945 is achieving pharmacologically active levels in plasma and in tumor cells and elicits a clear pharmacodynamic response.

"Clinical advancement of our first-in-class CK2 inhibitor, CX-4945, in patients with multiple myeloma represents another major milestone for Cylene. Moreover, the accompanying financing enables us to support the clinical trials and the expansion of our pipeline with high quality candidates emerging from our internal drug discovery platform.  The financing also illustrates the enthusiasm our investors have for CX-4945 and our highly original drug discovery platform," said Dr. William G. Rice, President and CEO of Cylene Pharmaceuticals.

"Our firm invests in companies that have the potential to lead innovations critical to the needs of patients, possess strong management expertise, perform novel proprietary science coupled with a mechanistic understanding of target diseases, and are capital-efficient with the potential to deliver substantial returns to shareholders. Cylene certainly fits these parameters," said Dr. Reinhard Ambros, Executive Director of the Novartis Venture Funds and Director of Cylene.  "Cylene's clinical development efforts, led by Dr. Daniel Von Hoff, lead the industry in targeting CK2 with potent and selective inhibitors for the treatment of various forms of cancer. This combination of features makes Cylene an attractive and exciting investment."

About Cylene Pharmaceuticals

Cylene Pharmaceuticals, Inc. is a San Diego-based, private biotechnology company discovering and developing targeted small molecule drugs to treat life-threatening cancers. Cylene's drug discovery platform, STAND (Selective TArgeting of Non-Oncogene Networks in Disease), has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support and maintenance of cancer cells and that address unmet medical needs with substantial markets. Cylene's novel agents include oral inhibitors of the cancer-linked serine/threonine protein kinases (CK2 and Pim), as well as oral agents that activate p53 via modulation of RNA Polymerase I activity in the upstream ribosome biogenesis pathway. Cylene's innovative platform enables the rapid discovery of first-in-class agents that exert antitumor activity as a single agent and that can mechanistically enhance the effectiveness of current cancer therapies. For more information on Cylene and its programs, please visit www.cylenepharma.com.


'/>"/>
SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
11. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):